Abstract
Psoriasis is now considered a chronic inflammatory and proliferative skin disease mediated by lymphocytes. In European countries, the prevalence of psoriasis is 1%~3%, so the study of psoriasis is very important. Through research into immune pathogenesis and advances in genetic engineering techniques, it has progressively developed a wide range of biological agents with promising results in clinical trials or treatments. This paper discusses the typical clinical manifestations, genetic research and treatment of psoriasis.
Publisher
Century Science Publishing Co
Reference25 articles.
1. Christopher EM Griffiths, Jonathan NWN Barker. Pathogenesis and clinical features of psoriasis[J]. The Lancet,2007,370(9583).
2. SHI Yu-ling. Interpretation of guideline for the diagnosis and treatment of psoriasis in China (2018 edition) [J]. JOURNAL OF TONGJI UNIVERSITY (MEDICAL SCIENCE), 2019, 40(03): 265-267. DOI:10.16118/j.1008-0392.2019.03.001.
3. DAI Dan, CHEN Yanhua, HE Chunyan, WANG Shuo, SONG Ping. Targeted Lipidomics Reveals Lipids Modulation of Kaixuan Bushen Method on Psoriasis Vulgaris. [J/OL]. Chinese Journal of Experimental Traditional Medical Formulae: 1-9[2022-10-19]. DOI:10.13422/j.cnki.syfjx.20220749.
4. Kudsi Mayssoun, Alzabibi Mhd Amin, Shibani Mosa. Two cases of Erythrodermic psoriasis treated with Golimumab[J]. Annals of Medicine and Surgery,2022,78.
5. Misha Rosenbach, Sylvia Hsu, Neil J. Korman, Mark G. Lebwohl, Melodie Young, Bruce F. Bebo, Abby S. Van Voorhees. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation[J]. Journal of the American Academy of Dermatology,2009,62(4).